Because a pharmaceutical company cant monetize it because theres no patent on it, so I dont know when were ever going to get the real truth on this thing, because nobodys putting billions of dollars into researching it, because nobodys going to monetize it
Phase 2B results for AOD9604 do not support commercial viability (obesity indication)
The published research literature has investigated: Angiogenic effects (formation of new blood vessels in damaged tissue) VEGFR2 receptor activity modulation Growth factor expression Tissue protection in gastrointestinal, vascular, and musculoskeletal contexts Wound healing in multiple tissue models GHK-Cu mechanisms
B12 Shot in Murray Mobile IV Therapy Murray, UT B12 Shot in Midvale Mobile IV Therapy Midvale, UT B12 Shot in Sandy Mobile IV Therapy Sandy, UT B12 Shot in Cottonwood Heights Mobile IV Therapy Cottonwood Heights, UT B12 Shot in Holladay Mobile IV Therapy Holladay, UT B12 Shot in South Jordan Mobile IV Therapy South Jordan, UT B12 Shot in South Salt Lake Mobile IV Therapy South Salt Lake, UT B12 Shot in Millcreek Mobile IV Therapy Millcreek, UT B12 Shot in Draper Mobile IV Therapy Draper, UT B12 Shot in Park City Mobile IV Therapy Park City, UT Ready for Your B12 Shot
All products are research reagents onlynot for human use
BPC-157 is a synthetic pentadecapeptide stabilised against acid hydrolysis, acting through multiple receptor systems including VEGFR2, FAK (focal adhesion kinase), EGR1 (early growth response protein 1), and eNOS to produce angiogenesis, tissue repair, anti-inflammatory, and neuroprotective effects
